Authors: Meghoufel, Z; Cherifi, F; Boukra, A; Terki, F; Porsbjerg, Celeste; Menzies-Gow, Andrew; Tran, Trung; Murray, Ruth; Unni, Bindhu; Audrey Ang, Shi Ling; Alacqua, Marianna; Al-Ahmad, Mona; Al-Lehebi, Riyad; Altraja, Alan; Belevskiy, Andrey; Björnsdóttir, Unnur; Bourdin, Arnaud; Busby, John; Canonica, G. Walter; Christoff, George; Cosio, Borja; Costello, Richard; FitzGerald, J. Mark; Fonseca, João; Hansen, Susanne; Heaney, Liam; Heffler, Enrico; Hew, Mark; Iwanaga, Takashi; Jackson, David; Kocks, Janwillem W.H.; Kallieri, Maria; Bruce Ko, Hsin-Kuo; Koh, Mariko Siyue; Larenas-Linnemann, Désirée; Lehtimäki, Lauri; Loukides, Stelios; Lugogo, Njira; Maspero, Jorge; Papaioannou, Andriana; Perez-de-Llano, Luis; Pitrez, Paulo Márcio; Popov, Todor; Rasmussen, Linda; Rhee, Chin Kook; Sadatsafavi, Mohsen; Schmid, Johannes; Siddiqui, Salman; Taillé, Camille; Taube, Christian; Torres-Duque, Carlos; Ulrik, Charlotte; Upham, John; Wang, Eileen; Wechsler, Michael; Bulathsinhala, Lakmini; Carter, Victoria; Chaudhry, Isha; Eleangovan, Neva; Hosseini, Naeimeh; Rowlands, Mari-Anne; Price, David; van Boven, Job FM.

Venue: The Journal of Allergy and Clinical Immunology: In Practice

Type: Publication

Abstract: Regulatory bodies have approved five biologics for severe asthma. However, regional differences in accessibility may limit the global potential for personalized medicine.To compare global differences in ease of access to biologics.In April 2021, national prescription criteria for omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab were reviewed by severe asthma experts collaborating in the International Severe Asthma Registry. Outcomes (per country, per biologic) were (1) country-specific prescription criteria and (2) development o... (read more)

DOI: 10.1016/j.jaip.2021.12.027